Home›Nitisinone

Nitisinone

Also known as: Orfadin

4-Hydroxyphenyl-Pyruvate Dioxygenase InhibitorHydroxyphenylpyruvate Dioxygenase InhibitorsCytochrome P450 2C9 Inhibitors

Route: Oral

Check Nitisinone Interactions →
8 interactions on record

Nitisinone has 8 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Phenytoin, Sensitive Cyp3a Substrates, Warfarin. Patients taking Nitisinone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
8
Major
3
Moderate
5

Major (3)

  • Nitisinone + Phenytoin— Nitisinone inhibits CYP2C9, significantly increasing phenytoin exposure. Reduce dosage by half and adjust to maintain th…
  • Nitisinone + Sensitive Cyp3a Substrates— Nitisinone is a moderate CYP2C9 inhibitor that may increase exposure of co-administered drugs metabolized by CYP2C9, req…
  • Nitisinone + Warfarin— Nitisinone inhibits CYP2C9, significantly increasing warfarin exposure. Reduce dosage by half and adjust to maintain the…

Moderate (5)

  • Nitisinone + Adefovir— OAT1/OAT3 Substrates (e.g., adefovir, ganciclovir, methotrexate) Clinical Impact Increased exposure of the interacting d…
  • Nitisinone + Celecoxib— Nitisinone is a moderate CYP2C9 inhibitor that increases exposure of celecoxib. Dosage reduction by half is recommended …
  • Nitisinone + Ganciclovir— OAT1/OAT3 Substrates (e.g., adefovir, ganciclovir, methotrexate) Clinical Impact Increased exposure of the interacting d…
  • Nitisinone + Methotrexate— Nitisinone is an inhibitor of OAT1/OAT3 that increases exposure of methotrexate. Monitor for potential adverse reactions…
  • Nitisinone + Tolbutamide— Nitisinone is a moderate CYP2C9 inhibitor that increases exposure of tolbutamide. Dosage reduction by half is recommende…

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations